The current valuation score of Madrigal Pharmaceuticals Inc is 9.67, ranking 18 out of 389 in the Biotechnology & Medical Research industry. Its current P/E ratio is -37.10, which is -88.09% below the recent high of -4.42 and -25.84% above the recent low of -46.69.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.